Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR

Table 1 Patient background characteristics and pathological response to neoadjuvant chemotherapy

Treatment group		Total	A1	A2	B1	B2
Patient number		66	15	18	17	16
Age, years	Median	54	44	47	58	56
Age, years	min.–max.	26–70	31–64	26–63	35–70	41–70
T	T1c	13	5	3	2	3
	T2	48	9	13	14	12
	T3	5	1	2	1	1
N	N0	39	7	11	11	10
N	N1	27	8	7	6	6
Histological grade (B and R)	1	2	1	0	0	1
	2	17	2	4	5	6
	3	44	11	14	11	8
	Unknown	3	1	0	1	1
Ki67 labeling index, %	Median	57.7	55	64.2	51.6	50.4
Ki67 labeling index, %	min.–max.	16.2–90	20.2–90	36.4–89.6	20–89	16.2–82
HRD	Low	18	0	0	9	9
	High	33	15	18	0	0
	Unknown	15	0	0	8	7
tBRCA1/2 mutation	BRCA1 mutation	6	3	3	0	0
	BRCA2 mutation	6	3	3	0	0
	No mutation	43	9	12	12	10
	Unknown	11	0	0	5	6
pCR	Yes	23	10	8	2	3
	No	43	5	10	15	13
	%	34.8	66.7	44.4	11.8	18.8

A1 group taking paclitaxel + carboplatin, A2 group taking eribulin + carboplatin, B1 eribulin + cyclophosphamide, B2 eribulin + capecitabine, HRD homologous recombination deficiency, tBRCA tumor BRCA, max. maximum, min. minimum, pCR pathological complete response

ISSN: 1741-7015